China Sky One Medical, Inc. received production approval for three injected products, including a propyl gallate injection for the treatment of acute cerebral infarction, coronary heart disease, thrombosis, dysmenorrheal and nephropathy. China Sky One expects to launch its propyl gallate injection product in August. The company projects that it will produce Q4 revenues of $3 million. More details...

Stock Symbol: (AMEX: CSY)